Skip to main content

Advertisement

SpringerLink
Log in

Malignant gliomas

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Malignant gliomas are the most common type of primary brain tumor. Although therapy for patients with these tumors remains limited, there has been important progress recently. In this review, some of these advances are discussed, with an emphasis on targeted molecular therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Central Brain Tumor Registry of the United States: CBTRUS 2002–2003. Statistical Report: Primary Brain Tumors in the United States, 1995–1999. Chicago: CBTRU; 2002.

    Google Scholar 

  2. Levin VA, Leibel SA, Gutin PH: Neoplasms of the central nervous system. In Cancer: Principles & Practice of Oncology, edn 6. Edited by De Vita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2001:2100–2103.

    Google Scholar 

  3. Dinnes J, Cave C, Huang S, Milne R: A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 2002, 86:501–505.

    Article  PubMed  CAS  Google Scholar 

  4. Yung WY, Prados MD, Yaya TR, et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytomas or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999, 17:2762–2771.

    PubMed  CAS  Google Scholar 

  5. Yung WY, Albright RE, Olson J, et al.: A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:589–593.

    Article  Google Scholar 

  6. Van Rijn J, Heimans JJ, van der Berg J, et al.: Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000, 47:779–784.

    Article  PubMed  Google Scholar 

  7. Stupp R, Dietrich PY, Kraljevic SO, et al.: Promising survival for patients with newly-diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375–1382. Phase II study showing benefit of concomitant temozolomide with radiation therapy.

    Article  PubMed  CAS  Google Scholar 

  8. Newlands ES, Foster T, Zaknoen S: Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 2003, 89:248–251.

    Article  PubMed  CAS  Google Scholar 

  9. Korones DN, Benita-Weiss M, Coyle TE, et al.: Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 2003, 97:1963–1968.

    Article  PubMed  CAS  Google Scholar 

  10. Gilbert M, Wen P, Lieberman F, et al.: Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) study [abstract]. Proc Am Soc Clin Oncol 2003, 410.

  11. Prados MD, Yung WK, Fine HA, et al.: Phase II study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium Study. Neurooncology 2004, 6:33–37.

    CAS  Google Scholar 

  12. Jaeckle KA, Hess KR, Yung WK, et al.: Phase II evaluation of temozolomide and 13-cis-Retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol 2003, 21:2305–2311.

    Article  PubMed  CAS  Google Scholar 

  13. Wong ET, Hess KR, Gleason MJ, et al.: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572–2578.

    PubMed  CAS  Google Scholar 

  14. Groves MD, Puduvalli VK, Hess KR, et al.: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383–1388.

    Article  PubMed  CAS  Google Scholar 

  15. Houghton PJ, Cheshire PJ, Hallman JD, et al.: Efficacy of the topoisomerase I inhibitors topotecan and irinotecan, administered in low doses in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995, 36:393–403.

    PubMed  CAS  Google Scholar 

  16. Buckner JC, Reid JM, Wright K, et al.: Irinotecan in the treatment of glioma patients. Current and future treatments of the North Central Cancer Treatment Group. Cancer 2003, 97(suppl 9):2352–2358.

    Article  PubMed  CAS  Google Scholar 

  17. Batchelor TT, Gilbert MR, Supko JG, et al.: Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro-oncology 2004, 6:21–27.

    Article  PubMed  CAS  Google Scholar 

  18. Friedman HS, Petros WP, Friedman AH, et al.: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999, 17:1516–1525.

    PubMed  CAS  Google Scholar 

  19. Prados MD, Yung WY, Jaeckle KA, et al.: Phase I trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain tumor Consortium study. Neurooncology 2004, 6:44–54.

    CAS  Google Scholar 

  20. Gilbert MR, Supko JG, Batchelor T, et al.: Phase I clinical trial and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003, 9:2940–2949.

    PubMed  CAS  Google Scholar 

  21. Raymond E, Fabbro M, Boige V, et al.: Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomas. Ann Oncol 2003, 14:603–614.

    Article  PubMed  CAS  Google Scholar 

  22. Cloughesy TF, Filka E, Kuhn J, et al.: Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003, 97(suppl 9):2381–2386.

    Article  PubMed  CAS  Google Scholar 

  23. Chamberlain MC: Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neuro-oncol 2002, 56:183–188.

    Article  Google Scholar 

  24. Jendrossek V, Belka C, Bamberg M: Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin Invest Drugs 2003, 12:1899–1924.

    Article  CAS  Google Scholar 

  25. Weller M, Muller B, Koch R, et al.: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003, 21:3276–3284.

    Article  PubMed  CAS  Google Scholar 

  26. Quinn JA, Pluda J, Dolan ME, et al.: Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourearesistant recurrent or progressive malignant glioma. J Clin Oncol 2002, 20:2277–2283.

    Article  PubMed  CAS  Google Scholar 

  27. Westphal M, Lamszus K, Hilt D: Intracavitary chemotherapy for glioblastoma: present status and future directions. Acta Neurochir Suppl 2003, 88:61–67.

    PubMed  CAS  Google Scholar 

  28. Guerin C, Olivi A, Weingart JD, et al.: Recent Advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 2004, 22:27–37.

    Article  PubMed  CAS  Google Scholar 

  29. Brem H, Piantadosi S, Burger PC, et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent malignant gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1999, 345:1008–1012.

    Article  Google Scholar 

  30. Westphal M, Hilt DC, Bortey E, et al.: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003, 5:79–88.

    Article  PubMed  CAS  Google Scholar 

  31. Olivi A, Grossman SA, Tatter S, et al.: Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: A New Approaches To Brain Tumor Therapy CNS Consortium Trial. J Clin Oncol 2003, 21:1845–1849.

    Article  PubMed  CAS  Google Scholar 

  32. Husain SR, Puri RK: Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neuro-oncol 2003, 65:37–48.

    Article  Google Scholar 

  33. Kunwar S, Prados M, Chang S, et al.: Peritumoral convectionenhanced delivery of IL-13-PE38QQR in patients with recurrent malignant glioma-phase I interim results [abstract]. Neuro-oncology 2003, 5:350.

    Google Scholar 

  34. Weber FW, Floeth F, Asher A: Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003, 88:93–103.

    PubMed  CAS  Google Scholar 

  35. Kawakami M, Kawakami K, Puri RK: Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neuro-oncol 2003, 65:15–25.

    Article  Google Scholar 

  36. Sampson JH, Akabanai G, Archer GE, et al.: Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neuro-oncol 2003, 65:27–35.

    Article  Google Scholar 

  37. Mamelak AN, Raubitschek A, Morgan R, et al.: A Phase I/II trial of intracavitary 131I-TM-601 in adult patients with recurrent high-grade-glioma [abstract]. Neuro-oncology 2003, 5:340.

    Google Scholar 

  38. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988, 23:360–364.

    Article  PubMed  CAS  Google Scholar 

  39. Cairncross JG, Macdonald DR, Ludwin S, et al.: Chemotherapy for oligodendroglioma. J Clin Oncol 1994, 12:2013–2021.

    PubMed  CAS  Google Scholar 

  40. van den Bent M, Chinot OL, Cairncross JG: Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncology 2003, 5:128–138.

    Article  PubMed  Google Scholar 

  41. Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473–1479.

    Article  PubMed  CAS  Google Scholar 

  42. Ino Y, Betensky RA, Zlatescu MC, et al.: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001, 7:839–845.

    PubMed  CAS  Google Scholar 

  43. Abrey LE, Childs BH, Paleologos N, et al.: High-dose chemotherapy with stem cell rescue for anaplastic oligodendroglioma. J Neuro-oncol 2003, 65:127–134.

    Article  Google Scholar 

  44. Chinot O, Honore S, Barre M, et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001, 19:2449–2455.

    PubMed  CAS  Google Scholar 

  45. Peterson K, Paleologos N, Forsyth P, et al.: Salvage chemotherapy for oligodendrogliomas. J Neurosurgery 1996, 85:597–601.

    Article  CAS  Google Scholar 

  46. Van den Bent MJ, Chinot O, Boogerd W, et al.: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomusting and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study of 26972. Ann Oncol 2003, 14:599–602.

    Article  PubMed  Google Scholar 

  47. Van den Bent MJ, Taphoorn MJ, Brandes AA, et al.: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003, 13:2525–2528.

    Article  CAS  Google Scholar 

  48. Maher EA, Furnari FB, Bachoo RM, et al.: Malignant glioma: genetics and biology of a grave matter. Gene Dev 2001, 15:1311–1333.

    Article  PubMed  CAS  Google Scholar 

  49. Kitange GJ, Templeton KL, Jenkins RB: Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 2003, 15:197–203.

    Article  PubMed  CAS  Google Scholar 

  50. Konopka G, Bonni A: Signaling pathways regulating gliomagenesis. Curr Mol Med 2003, 3:73–84.

    Article  PubMed  CAS  Google Scholar 

  51. van den Boom J, Wolter M, Kuick R, et al.: Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003, 163:1033–1043.

    PubMed  Google Scholar 

  52. Mischel PS, Nelson SF, Cloughesy TF: Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther 2003, 2:242–247.

    PubMed  CAS  Google Scholar 

  53. Rao RD, Uhm JH, Krishnan S, James CD: Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front Biosci 2003, 8:270–280.

    Article  Google Scholar 

  54. Shai R, Shi T, Kremen TJ, et al.: Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003, 22:4918–4923.

    Article  PubMed  CAS  Google Scholar 

  55. Nutt CL, Mani DR, Betensky RA, et al.: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003, 63:1602–1607.

    PubMed  CAS  Google Scholar 

  56. Drucker BJ: Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002, 1:31–36.

    Article  Google Scholar 

  57. Karpati G, Nalbantoglu J: The principles of molecular therapies for glioblastoma. Int Rev Neurobiol 2003, 55:151–163.

    Article  PubMed  CAS  Google Scholar 

  58. Newton HB: Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 1 -growth factor and ras signaling pathways. Expert Rev Anticancer Ther 2003, 3:595–614. Comprehensive review of targeted molecular therapies for brain tumors.

    Article  PubMed  CAS  Google Scholar 

  59. Newton HB: Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 2 - PI3K/Akt/PTEN, bdmTOR, SHH/PTCH, and Angiogenesis. Expert Rev Anticancer Ther 2004, In press. Comprehensive review of targeted molecular therapies for brain tumors.

  60. Mischel PS, Cloughesy TF: Targeted molecular therapy of glioblastoma. Brain Pathol 2003, 13:52–61.

    Article  PubMed  Google Scholar 

  61. Rich J, Reardon DA, Peery TS, et al.: Phase II trial of ZD1839 for patients with first relapse glioblastoma. J Clin Oncol 2004, 22:133–142.

    Article  PubMed  CAS  Google Scholar 

  62. Shinojima N, Tada K, Shiraishi S, et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63:6962–6970.

    PubMed  CAS  Google Scholar 

  63. Lieberman T, Cloughesy L, Deangelis L, et al.: Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy [abstract]. Am Soc Clin Oncol 2003, 22:105

    Google Scholar 

  64. Raizer JJ, Abrey L, Wen P, et al.: A Phase II trial of OSI-774 (Tarceva) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc Am Soc Clin Oncol 2004, In press.

  65. Prados M, Chang S, Burton E, et al.: Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma [abstract]. Am Soc Clin Oncol 2003, 394.

  66. Vogelbaum MA, Oeereboom D, Stevens G, et al.: Initial experience with the EGFR tyrosine kinase inhibitor traceva (OSI-774) for single-agent therapy of recurrent /progressive glioblastoma [abstract]. Society For Neuro-Oncology 8th Annual Meeting 2003. Neuro-oncology 2003, 5:356.

    Google Scholar 

  67. Chakravarti A, Chakladar A, Delaney MA, et al.: The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002, 62:4307–4315.

    PubMed  CAS  Google Scholar 

  68. Krishnan S, Rao RD, James CD, Sarkaria JN: Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Front Biosci 2003, 8:e1-e13.

    Article  PubMed  CAS  Google Scholar 

  69. Goudar R, Keir S, Hjelmeland M, et al.: Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma growth inhibition. Presented at AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA, November 17, 2003.

  70. Hermanson M, Funa K, Hartman L, et al.: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992, 52:3213–3219.

    PubMed  CAS  Google Scholar 

  71. Guha A, Dashner K, Black PM, et al.: In vivo expression of PDGF and PDGF receptors in human astrocytomas. Int J Cancer 1995, 60:168–173.

    Article  PubMed  CAS  Google Scholar 

  72. Kilic T, Alberta J, Zdunek PR, et al.: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000, 60:5143–5150.

    PubMed  CAS  Google Scholar 

  73. Wen PY, Yung WK, Hess K, et al.: Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99-08). Proc Am Soc Clin Oncol 2002, 73:Abstr 291.

    Google Scholar 

  74. Dai H, Marbach P, Lemaire M, et al.: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003, 304:1085–1092.

    Article  PubMed  CAS  Google Scholar 

  75. de Bono JS, Tolcher AW, Rowinsky EK: Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Semin Oncol 2003, 30(suppl 16):79–92.

    PubMed  Google Scholar 

  76. Cloughesy TF, Kuhn J, Wen P, et al.: Two phase II trails of R115777 (Zarnestra) in patients with recurrent glioblastoma multiforme: A comparison of patients on enzyme-induing anti-epileptic drugs (EIAED) and not on EIAED at maximum tolerated dose respectively [abstract]: A North American Brain Tumor Comnsortium (NATC) Report. Neuro-oncology 2003, 5:349.

    Google Scholar 

  77. Mita MM, Mita A, Rowinsky EK: The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003, 2(suppl 1):S169-S177.

    PubMed  CAS  Google Scholar 

  78. Geoerger B, Kerr K, Tang CB, et al.: Antitumor activity of the Rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001, 61:1527–1532.

    PubMed  CAS  Google Scholar 

  79. Chang S, Kuhn J, Wen P, et al.: Phase I pharmacokinetic study of CCI-779 in recurrent malignant glioma on enzyme-inducing antiepileptic drugs. 15th International Conference on Brain Tumor Research and Therapy, 2003. Neuro-oncology 2003, 5:377.

    Google Scholar 

  80. Chang S, Kuhn J, Wen P, et al.: Phase II pharmacokinetic Study of CCI-779 in recurrent glioblastoma multiforme. Society For Neuro-Oncology 8th Annual Meeting 2003. Neuro-oncology 2003, 5:349.

    Google Scholar 

  81. Readon D, Friedman H, Yung WK, et al.: A phase I trial of PTK787/ZK 222584 (PTK/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2003, Abstr 412.

  82. Choe G, Horvath S, Cloughesy TF, et al.: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003 1:2742–2746.

    Google Scholar 

  83. Tjuvajev JG, Blasberg R: In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell 2003, 3:327–332.

    Article  CAS  Google Scholar 

  84. Fine HA, Wen PY, Maher EA, et al.: Phase II trial of thalidomide and carmustine for patients with recurrent high-gradegliomas. J Clin Oncol 2003, 21:2299–2304.

    Article  PubMed  CAS  Google Scholar 

  85. Lamszus K, Kunkel P, Westphal M: Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 2003, 88:169–177.

    PubMed  CAS  Google Scholar 

  86. Rainov NG, Ren H: Clinical trials with retrovirus mediated gene therapy—what have we learned? J Neuro-oncol 2003, 65:227–236.

    Article  Google Scholar 

  87. Shah AC, Benos D, Yancey Gillespie G, Markert JM: Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neuro-oncol 2003, 65:203–226.

    Article  Google Scholar 

  88. Germano IM, Fable J, Gultekin SH, Silvers A: Adenovirus/ herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neuro-oncol 2003, 65:279–289.

    Article  Google Scholar 

  89. Prados MD, McDermott M, Chang SM, et al.: Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vectorproducer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J Neuro-oncol 2003, 65:269–278.

    Article  Google Scholar 

  90. Vecil GG, Lang FF: Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neuro-oncol 2003, 65:237–246.

    Article  Google Scholar 

  91. Lang FF, Bruner JM, Fuller GN, et al.: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003, 21:2505–2518.

    Google Scholar 

  92. Castro MG, Cowen R, Williamson IK: Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003, 98:71–108.

    Article  PubMed  CAS  Google Scholar 

  93. Laura K, Aguilar LK, Aguilar-Cordova E: Evolution of a gene therapy clinical trial. From bench to bedside and back. J Neuro-oncol 2003, 65:307–315.

    Article  Google Scholar 

  94. Kanzawa T, Ito H, Kondo Y, Kondo S: Current and future gene therapy for malignant gliomas. J Biomed Biotech 2003, 1:25–34.

    Article  Google Scholar 

  95. Reardon DA, Gamal AG, Coleman ER, et al.: Phase II trial of murine 131 I-labeled antitenascin monoclonal antibody 81c6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002, 20:1389–1397.

    Article  PubMed  CAS  Google Scholar 

  96. Goetz C, Riva P, Poepperl G, et al.: Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neuro-oncol 2003, 62:321–328.

    Article  CAS  Google Scholar 

  97. Yang L, Ng KY, Lillehei KO: Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 2003, 10:138–147.

    PubMed  Google Scholar 

  98. Fecci PE, Mitchell DA, Archer GE, et al.: The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neuro-oncol 2003, 64161–64176.

  99. Yamanaka R, Abe T, Yajima N, et al.: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003, 89:1172–1179.

    Article  PubMed  CAS  Google Scholar 

  100. Yu JS, Wheeler CJ, Zeltzer PM, et al.: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001, 61:842–847.

    PubMed  CAS  Google Scholar 

  101. Okada H, Lieberman FS, Edington HD, et al.: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neuro-oncol 2003, 64:13–20.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Neuro-Oncology, Dana Farber Cancer Institute, SW430D, 44 Binney Street, 02115, Boston, MA, USA

    Patrick Y. Wen MD & Santosh Kesari MD, PhD

Authors
  1. Patrick Y. Wen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Santosh Kesari MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wen, P.Y., Kesari, S. Malignant gliomas. Curr Neurol Neurosci Rep 4, 218–227 (2004). https://doi.org/10.1007/s11910-004-0042-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-004-0042-4

Keywords

Search

Navigation